Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction

Birgit Steppich; Martin Hadamitzky; Tareq Ibrahim; Philip Groha; Heribert Schunkert; Karl-Ludwig Laugwitz; Adnan Kastrati; Ilka Ott; for the Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Study Investigators

doi:10.1160/TH15-07-0589

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 115(04): 864-868
DOI: 10.1160/TH15-07-0589

Atherosclerosis and Ischaemic Disease

Schattauer GmbH

Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction

Long-term results of the REVIVAL-2 trial

Birgit Steppich

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

Martin Hadamitzky

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

Tareq Ibrahim

²Klinikum rechts der Isar, 1. Medizinische Klinik, München, Germany

,

Philip Groha

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

Heribert Schunkert

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

Karl-Ludwig Laugwitz

²Klinikum rechts der Isar, 1. Medizinische Klinik, München, Germany

,

Adnan Kastrati

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

Ilka Ott

¹Deutsches Herzzentrum der Technischen Universität München, München, Germany

,

for the Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Study Investigators

› Author Affiliations

Abstract

Summary

Treatment with granulocyte-colony stimulating factor (G-CSF) mobilises cells from the bone marrow to the peripheral blood. Previous preclinical and early clinical trials may suggest that treatment with G-CSF leads to improved myocardial perfusion and function in acute or chronic ischaemic heart disease. In the REVIVAL-2 study we found that stem cell mobilisation by G-CSF does not influence infarct size, left ventricular function and coronary restenosis in patients with acute myocardial infarction (MI) that underwent successful percutaneous coronary intervention. The objective of the present analysis was to assess the impact of G-CSF treatment on seven-year clinical outcomes from the REVIVAL-2 trial. In the randomized, double-blind, placebo-controlled REVIVAL-2 study, 114 patients with the diagnosis of acute myocardial infarction were enrolled five days after successful reperfusion by percutaneous coronary intervention. Patients were assigned to receive 10 μg/kg G-CSF (n=56) or placebo (n=58) for five days. The primary endpoint for this long-term outcome analysis was the composite of death, myocardial infarction or stroke seven years after randomisation. The endpoint occurred in 14.3% of patients in the G-CSF group versus 17.2%> assigned to placebo (p=0.67). The combined incidence of death or myocardial infarction occurred in 14.3%> of the patients assigned to G-CSF and 15.5%> of the patients assigned to placebo (p=0.85). In conclusion, these long-term follow-up data show that G-CSF does not improve clinical outcomes of patients with acute myocardial infarction.

Keywords

Clinical studies - acute myocardial infarction - cardiology - granulocyte-colony stimulating factor - stem cells

Full Text

References

References
1 Zohlnhöfer D, Ott I, Mehilli J. et al. Stem cell mobilisation by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. J Am Med Assoc 2006; 295: 1003-1010.
2 San Roman JA, Sánchez PL, Villa A. et al. Comparison of Different Bone Marrow-Derived Stem Cell Approaches in Reperfused STEMI: A Multicenter, Prospective, Randomized, Open-Labeled TECAM Trial. J Am Coll Cardiol 2015; 65: 2372-2382.
3 Orlic D, Kajstura J, Chimenti S. et al. Mobilized bone marrow cells repair the in-farcted heart, improving func- tion and survival. Proc Natl Acad Sci USA 2001; 98: 10344-10349.
4 Kajstura J, Rota M, Whang B. et al. Bone marrow cells differentiate in cardiac cell lineages after infarc- tion independently of cell fusion. Circ Res 2005; 96: 127-137.
5 Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005; 85: 1373-1416.
6 Minatoguchi S, Takemura G, Chen XH. et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004; 109: 2572-2580.
7 Ohki Y, Heissig B, Sato Y. et al. Granulocyte colony- stimulating factor promotes neovascularisation by re- leasing vascular endothelial growth factor from neutrophils. FASEB J 2005; 19: 2005-2007.
8 Sugano Y, Anzai T, Yoshikawa T. et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 2005; 65: 446-456.
9 Clifford DM, Fisher SA, Brunskill SJ. et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; 02: CD006536.
10 Moazzami K, Roohi A, Moazzami B. Granulocyte colony stimulating factor therapy for acute myocardial infarction. Cochrane Database Syst Rev 2013; 05: CD008844.
11 Baldo MP, Davel AP, Nicoletti-Carvalho JE. et al. Granulocyte colony-stimulating factor reduces mortality by suppressing ventricular arrhythmias in acute phase of myocardial infarction in rats. J Cardiovasc Pharmacol 2008; 52: 375-380.
12 Ripa RS, Jørgensen E, Kastrup J. Clinical outcome after stem cell mobilisation with granulocyte-colony-stimulating factor after acute ST-elevation myocardial infarction: 5-year results of the STEMMI trial. Scand J Clin Lab Invest 2013; 73: 125-129.
13 Ripa RS, Jørgensen E, Wang Y. et al. Stem cell mobilisation induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem cells in Myocardial Infarction(STEM-MI)trial. Circulation 2006; 113: 1983-1992.
14 Achilli F, Malafronte C, Maggiolini S. et al. G-CSF treatment for STEMI: final 3-year follow-up of the randomised placebo-controlled STEM-AMI trial. Heart 2014; 100: 574-581.
15 Sato D, Otani H, Fujita M. et al. Granulocyte colony-stimulating factor does not enhance recruitment of bone marrow-derived cells in rats with acute myocardial infarction. Exp Clin Cardiol 2012; 17: 83-88.
16 Taghavi S. George JC Homing of stem cells to ischaemic myocardium. Am J Transl Res 2013; 05: 404-411.
17 Shah VK, Shalia KK. Stem Cell Therapy in Acute Myocardial Infarction: A Pot of Gold or Pandora’s Box. Stem Cells Int 2011; 2011: 536758.
18 Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischaemic cardiomyopathy. Expert Opin Biol Ther 2010; 10: 321-335.
19 Vagima Y, Lapid K, Kollet O. et al. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods Mol Biol 2011; 750: 277-289.
20 Stein A, Zohlnhöfer D, Pogatsa-Murray G. et al. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb Haemost 2010; 103: 638-643.
21 Gnecchi M, Zhang Z, Ni A. et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219.
22 Steppich BA, Demetz G, Schulz S. et al. Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. Thromb Res 2011; 127: 119-121.
23 Kang S, Yang Y, Li C. et al. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Clinical Therapeutics 2007; 29: 2406-2418.
24 Steinwender C, Hofmann R, Kypta A. et al. Late stent thrombosis after transcor-onary transplantation of granulocyte-colony stimulating factor-mobilized peripheral blood stem cells following primary percutaneous intervention for acute myocardial infarction. Int J Cardiol 2007; 122: 248-249.